A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus

The New England Journal of Medicine
S C ShahN E Simpson

Abstract

A period of early, intensive insulin treatment is thought to improve subsequent beta-cell function in insulin-dependent diabetes mellitus (IDDM). To study this hypothesis, we randomly assigned adolescents with newly diagnosed IDDM to receive either conventional treatment (n = 14) (NPH insulin, 1 U per kilogram of body weight per day, in two divided doses) or an experimental treatment (n = 12) (a two-week hospitalization with maintenance of blood glucose levels between 3.3 and 4.4 mmol per liter by continuous insulin infusion delivered by an external artificial pancreas [Biostator]). During the two-week intervention, the experimental-therapy group received four times more insulin than the conventionally treated group, and their endogenous insulin secretion was more completely suppressed, as evidenced by a urinary C-peptide excretion rate one seventh that of the conventionally treated group. After the first two weeks, both groups were treated similarly and received similar amounts of insulin. At one year, the mean (+/- SEM) plasma level of C peptide was significantly higher after mixed-meal stimulation in the experimental-therapy group than in the conventionally treated group (0.51 +/- 0.07 vs. 0.27 +/- 0.06; P less than 0.01). T...Continue Reading

References

Mar 1, 1991·Diabetes/metabolism Reviews·D AndreaniP Pozzilli
Dec 1, 1993·Diabetes/metabolism Reviews·U Di Mario, F Dotta
Dec 1, 1993·Diabetes/metabolism Reviews·A G ZieglerW Rabl
Sep 1, 1994·Diabetologia·C BoitardJ F Bach
Jan 1, 1996·Springer Seminars in Immunopathology·P Luppi, M Trucco
Jul 28, 2013·Current Diabetes Reports·Leonard C HarrisonGrant Morahan
Jan 1, 1995·Molecular Aspects of Medicine·W J KargesH M Dosch
Aug 8, 1992·Lancet·S C Bain, J A Todd
Oct 1, 1996·Immunology Today·F Homo-Delarche, C Boitard
Jun 1, 1994·Molecular and Cellular Endocrinology·L A VellosoD L Eizirik
Sep 1, 1996·Diabetes Research and Clinical Practice·Y KainoK Kida
Mar 1, 1997·Diabetes Research and Clinical Practice·J Ludvigsson, S Hellström
Sep 1, 1996·Trends in Endocrinology and Metabolism : TEM·V K Ramiya, N Maclaren
Jan 9, 2008·Immunology and Cell Biology·Leonard C Harrison
Mar 19, 1999·Journal of Internal Medicine·A SchölinE Björk
May 5, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·C Zevaco-MatteiB Vialettes
Nov 24, 1994·The New England Journal of Medicine·M A Atkinson, N Maclaren
Nov 12, 2005·The New England Journal of Medicine·Michael J Haller, Desmond Schatz
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·L ChatenoudJ F Bach
Jan 19, 2002·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Staley A BrodW Riley
Feb 13, 2003·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Staley A Brod
Jan 5, 2002·Diabetes Technology & Therapeutics·K Lin-SuN Maclaren
Mar 5, 2003·Diabetes Technology & Therapeutics·William E WinterDesmond Schatz
Nov 18, 2006·Diabetes Technology & Therapeutics·Neesha RamchandaniN Maclaren
Sep 22, 2011·Diabetes Technology & Therapeutics·Jaime M Realsen, H Peter Chase
Apr 11, 2013·Diabetes Technology & Therapeutics·Bruce A BuckinghamMartin Cantwell

Citations

Jan 1, 1978·Diabetes·O K FaberA H Rubenstein
Sep 8, 1988·The New England Journal of Medicine·J SilversteinS Johnson
Mar 17, 1988·The New England Journal of Medicine·P BougnèresJ L Chaussain
May 22, 1986·The New England Journal of Medicine·G S Eisenbarth
Apr 1, 1985·Diabetes·J R BrennanW G Blackard

Related Concepts

Glycated Hemoglobin TEST
Depression, Chemical
Implantable Programmable Insulin Pump
Benign Tumor of Pancreas
C-Peptide
Weighing Patient
Insulin C-peptide Measurement
Visual Suppression
Body Excretions
Novolin

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.